Pacira BioSciences (NASDAQ:PCRX) CFO Shawn Cross Sells 12,941 Shares
by Amy Steele · The Cerbat GemPacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) CFO Shawn Cross sold 12,941 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $25.16, for a total value of $325,595.56. Following the completion of the transaction, the chief financial officer directly owned 105,341 shares in the company, valued at approximately $2,650,379.56. This trade represents a 10.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Shawn Cross also recently made the following trade(s):
- On Tuesday, April 21st, Shawn Cross sold 2,845 shares of Pacira BioSciences stock. The shares were sold at an average price of $25.01, for a total transaction of $71,153.45.
- On Wednesday, April 22nd, Shawn Cross sold 1,500 shares of Pacira BioSciences stock. The shares were sold at an average price of $25.01, for a total transaction of $37,515.00.
- On Monday, April 20th, Shawn Cross sold 7,714 shares of Pacira BioSciences stock. The shares were sold at an average price of $25.14, for a total value of $193,929.96.
Pacira BioSciences Trading Down 3.4%
PCRX traded down $0.85 during mid-day trading on Friday, hitting $24.51. 525,894 shares of the stock were exchanged, compared to its average volume of 473,242. The firm’s fifty day moving average is $23.09 and its two-hundred day moving average is $23.08. Pacira BioSciences, Inc. has a 1-year low of $18.80 and a 1-year high of $27.64. The company has a current ratio of 4.54, a quick ratio of 3.28 and a debt-to-equity ratio of 0.54. The company has a market cap of $992.41 million, a PE ratio of 163.40 and a beta of 0.19.
Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.57 EPS for the quarter, missing the consensus estimate of $0.85 by ($0.28). The business had revenue of $196.87 million during the quarter, compared to analysts’ expectations of $201.93 million. Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.39%. The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.91 EPS. Equities analysts forecast that Pacira BioSciences, Inc. will post 1.85 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Pacira BioSciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Inspire Investing LLC increased its holdings in shares of Pacira BioSciences by 3.2% in the 4th quarter. Inspire Investing LLC now owns 17,958 shares of the company’s stock valued at $465,000 after acquiring an additional 556 shares during the period. Hantz Financial Services Inc. boosted its stake in Pacira BioSciences by 175.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock worth $29,000 after purchasing an additional 721 shares during the period. State of Wyoming grew its position in Pacira BioSciences by 7.0% during the 4th quarter. State of Wyoming now owns 11,155 shares of the company’s stock worth $289,000 after purchasing an additional 728 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Pacira BioSciences by 8.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 10,604 shares of the company’s stock valued at $259,000 after purchasing an additional 785 shares during the period. Finally, Franklin Resources Inc. increased its stake in Pacira BioSciences by 2.6% in the fourth quarter. Franklin Resources Inc. now owns 33,860 shares of the company’s stock valued at $876,000 after purchasing an additional 846 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.
Analyst Ratings Changes
Several brokerages have recently weighed in on PCRX. Weiss Ratings reissued a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target on shares of Pacira BioSciences in a research note on Friday, January 9th. Barclays cut their price objective on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a report on Thursday, March 26th. Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Finally, Wall Street Zen downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $30.25.
View Our Latest Report on Pacira BioSciences
Pacira BioSciences Company Profile
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.